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Running title: Ultra-sensitive detection of IFNα in human diseases 
 
Short Caption: We report the direct quantification of interferon alpha protein in 
monogenic interferonopathies, autoimmunity and infectious disease states, made 
possible by the combination of digital ELISA and high-affinity autoantibodies isolated 
from APECED patients, revealing differential levels and cellular sources dependent 
on underlying pathology. 
 
 
Abbreviations 
AEB: Average enzyme per bead 
AGS: Aicardi-Goutières syndrome 
CNS: Central nervous system 
CSF: Cerebrospinal fluid 
JDM: Juvenile dermatomyositis 
IFN: Interferon 
IQ: Inter quartile (range) 
ISG: Interferon stimulated gene 
LOD: Limit of detection 
mABs: Monoclonal antibodies 
MDBK: Mardin-Darby bovine kidney cells 
RVCL: Retinal vasculopathy with cerebral leukodystrophy 
SLE: Systemic lupus erythematosus  
SLEDAI: Systemic lupus erythematosus disease activity index 
 
Type I interferons (IFNs) are essential mediators of anti-viral responses. These 
cytokines have been implicated in the pathogenesis of autoimmunity, most 
notably systemic lupus erythematosus (SLE), diabetes mellitus and 
dermatomyositis, as well as monogenic type I interferonopathies. Despite a 
fundamental role in health and disease, the direct quantification of type I IFNs 
has been challenging. Utilizing digital ELISA technology, we recorded 
attomolar concentrations of IFNα in healthy donors, viral infection and 
complex and monogenic interferonopathies. IFNα protein correlated well with 
functional activity and IFN stimulated gene expression. High circulating IFNα 
levels were associated with increased clinical severity in SLE patients, and a 
study of the cellular source of IFNα protein indicated disease-specific 
mechanisms. Measurement of IFNα attomolar concentrations by digital ELISA 
will enhance our understanding of IFN biology and potentially improve the 
diagnosis and stratification of pathologies associated with IFN dysregulation. 
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Introduction 
 
The identification of a soluble factor that protects cells from viral infection was first 
made by Isaacs and Lindenmann in 1957 (Isaacs and Lindenmann, 1957; Isaacs et 
al., 1957). We now know that multiple species of type I interferon (IFN) exist, with this 
heterogeneity arising from the presence of 13 functional α genes and one β gene 
situated syntenically on human chromosome 9p (Manry et al., 2011). However, 
despite almost 60 years of active research in this field, the direct measurement of 
type I IFN protein in biological samples has remained elusive. Type I IFN mRNA is 
usually present at only trace levels in peripheral blood mononuclear cells (PBMCs) 
from healthy individuals, and current ELISAs have proven either insensitive or 
unreliable, leading to the development of proxy assays based on type I IFN signaling 
(Berger Rentsch and Zimmer, 2011; Hua et al., 2006; Li et al., 2010; Niewold et al., 
2009; Seo et al., 2009). Such presumed low levels of circulating IFN protein likely 
reflect the high biological potency of these cytokines, with most cell types expressing 
a type I IFN receptor.  
 
Balanced against its beneficial role in anti-viral protection, non-physiological 
exposure to IFN can have major detrimental effects (Hunt et al., 2014). This point is 
well illustrated by the complex disorders systemic lupus erythematosus (SLE) and 
dermatomyositis (DM), and the recently defined group of monogenic 
autoinflammatory diseases referred to as the type I interferonopathies, where 
persistent type I IFN-induced signalling is considered causal to pathology (Crow, 
2011; Greenberg et al., 2005; Hooks et al., 1979; Rodero and Crow, 2016). However, 
the mechanistic dissection of these pathologies has been hampered by the inability 
to directly quantify the disease causing protein. This also represents a major unmet 
clinical need, since such a test could improve diagnosis and therapeutic monitoring in 
the context of infection, autoimmunity and type I interferonopathies.  
 
To overcome this limitation we took advantage of a new digital ELISA technology 
based on counting individual enzyme-labelled immunocomplexes of proteins 
captured on paramagnetic beads in Single Molecule Arrays (Simoa) (Rissin et al., 
2010; Wilson et al., 2015). Combining this technology with unique high affinity 
antibodies isolated from APS1/APECED mutation patients (Meyer et al., 2016) 
enabled the direct quantification of IFNα at attomolar (femtogram/ml) concentrations. 
With this five thousand-fold increase in sensitivity over commercial ELISAs, we could 
directly measure elevated IFNα protein in patients with adult and juvenile-onset SLE 
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(JSLE), juvenile-onset DM (JDM), a group of molecularly distinct type I 
interferonopathies and acute viral meningitis. IFN protein quantification by Simoa 
was highly correlated with IFN anti-viral activity and interferon stimulated gene (ISG) 
expression measured in serum and in the cerebrospinal fluid (CSF) of all patients 
examined. Finally, differences within disease groups were observed based on serum 
IFNα protein levels, and between diseases as indicated by the results of our studies 
on the cellular source of IFNα protein.  
 
These data show that the measurement of IFNα protein by digital ELISA is a 
sensitive, reliable and biologically relevant method that can be used for the 
diagnosis, stratification and therapeutic monitoring of pathological states associated 
with an upregulation of type I IFN signalling. The ability to directly measure IFNα 
protein levels will facilitate a better understanding of the nature, regulation and 
impact of the human IFN-induced response. 
 
Results and discussion: 
 
Direct quantification of IFNα in plasma, serum and cerebrospinal fluid 
 To confirm the specificity of our Simoa assay for human IFNα, and non-cross 
reactivity for other IFNs, we tested these antibodies against IFNβ, IFNλ1, IFNλ2, 
IFNω and IFNγ recombinant proteins (Fig. 1 A), and 16 subtypes of IFNα that 
included 3 commercially available IFNα2 types; namely IFNα2a, IFNα2b, IFNα2c 
(Fig. 1 B). Our assay did not cross-react with other IFNs and was able to detect all 
IFNα subtypes, although a lower affinity to IFNα2 was observed (Fig. S1 A). Because 
its standard curve was representative of all other subtypes, IFNα17 (IFNαI) was 
chosen as our reference protein. To further define the specificity of these reagents 
we performed a competition assay in plasma samples from 5 systemic lupus 
erythematosus (SLE) patients. Addition of anti-IFNα antibody depleted the signal, 
showing a specific detection of IFNα in the tested samples (Fig. 1 C). Reproducibility 
was assessed across 3 assays (Fig. 1 D), and the mean of three blanks +3SD was 
used to calculate the limit of detection (LOD). The mean of all LODs was calculated 
at 0.23 fg/ml, and this value was multiplied by our standard dilution factor (x 3) to 
give a measure of 0.69 fg/ml, which was used to replace all undetectable values for 
presentation purposes. Assay reproducibility was also assessed by the measurement 
of IFNα protein in 22 plasma samples from 8 SLE, 8 JDM, 3 Aicardi-Goutières 
syndrome (AGS) and 3 TMEM173-mutated / STING patients, using two 
independently prepared lots of beads, performed by different users at different times 
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(Rs = 0.978, p = 0.0001) (Fig. 1 E). Analyzing 10 matched plasma and serum 
samples from AGS patients revealed a strong correlation (Fig. 1 F, Rs = 0.958, p = 
0.0001), indicating a negligible influence of blood processing on IFNα concentration 
and the ability to use either sample for retrospective patient screening. 
 
To determine the potential diagnostic capability of our assay, we examined 
collections of plasma and serum established during the study of Mendelian type I 
interferonopathies (27 patients in total) - attributable to mutations in TREX1 (n = 4), 
RNASEH2A (n = 1), RNASEH2B (n = 6), RNASEH2C (n = 2), SAMHD1 (n = 2), 
ADAR1 (n = 2), IFIH1 (n = 3) and TMEM173 gain-of-function (n = 7) (STING). We 
also analysed samples from patients with JDM (n = 43), and SLE (n = 72) (both 
juvenile and adult forms; n = 6 and 66 respectively). We compared these data with 
samples from 20 healthy control subjects, and patients with specific autosomal 
dominant mutations in the 3’ end of TREX1 causing retinal vasculopathy and 
cerebral leucodystrophy (RVCL) which has not previously been associated with 
increased type I IFN signalling (n = 30). Clinical characteristics of these patient and 
control groups are described in Tables S1 – S6. A one-way ANOVA test (Kruskal-
Wallis), and Dunn’s post-test controlling for multiple comparison testing, revealed 
significantly elevated IFNα in the monogenic interferonopathy (p < 0.0001), JDM (p < 
0.0001) and SLE (p < 0.0001) groups as compared to healthy controls, confirming 
the previously recognised associations with these clinical phenotypes (Fig. 2 A). In 
contrast, RVCL patients showed no difference in comparison to healthy controls 
(median 1.6 fg/ml; Inter Quartile range (IQR) 0.95 - 4.6 fg/ml) (Fig. 2 A). Multiple 
group testing also demonstrated that patients with a molecularly determined 
interferonopathy had significantly higher IFNα (median 310 fg/ml; IQR 71 - 2223 
fg/ml) in comparison to SLE (median 20 fg/ml; IQR 0.69 - 234 fg/ml) (p < 0.001), but 
not to JDM (median 56 fg/ml; IQR 14 - 120 fg/ml) patients (Fig. 2 A).  
 
As expected given the fundamental role of IFN in antiviral protection, testing of CSF 
from patients with central nervous system (CNS) infection (acute meningitis, n = 9; 
acute encephalitis, n = 9; acute meningo-encephalitis, n = 1) revealed very high 
levels of IFNα protein (Fig. 2 B: median 4174.2 fg/ml; IQR 2437.4 - 11173 fg/ml). In 
contrast, all but one patient with RVCL (n = 12) demonstrated an IFNα protein level 
of less than 10 fg/ml (p < 0.001, Mann-Whitney test as compared to infection 
samples). 
 
IFNα concentration correlates with functional antiviral activity  
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To investigate the functional relevance of such low protein levels, we compared IFNα 
protein measurements with IFN activity as assessed by a cytopathic protection assay 
(Lebon et al., 1988; Lebon et al., 1979; Palmer et al., 2007). Specifically, IFN activity 
is determined by dilution of patient material incubated with Mardin-Darby bovine 
kidney cells. Cells are challenged the next day with vesicular stomatitis virus, and 
examined 18 hours post infection to measure the viral cytopathic effect. Cell 
protection against infection reveals the biological activity of type I IFN, which is 
compared with serial dilutions of an IFN standard. Comparing these assays on serum 
samples (Fig. 3 A: 25 JDM, 2 JSLE and 11 monogenic interferonopathy patients – 
either AGS or STING, Table S7) demonstrated a positive correlation (Rs = 0.83 p < 
0.0001). Considering the potential contribution of type I IFNs to CNS disorders, we 
performed a similar comparison on the CSF samples presented in Fig. 2 B. This 
analysis revealed an even stronger positive correlation between IFN activity and 
concentration (Rs = 0.924, p < 0.001). To note, statistical analysis was performed on 
samples with either detectable IFN activity (≥ 2 IU/ml) or IFN protein (> 0.69 fg/ml) 
(Fig. 3 B). Interestingly, 10 serum and 1 CSF samples had IFNα concentration > 10 
fg/ml with no detectable anti-viral activity, reflecting either the increased sensitivity of 
the Simoa assay or the presence of post-translational (or other) modifications that 
may alter functional potency. 
 
Comparison of IFNα concentration with ISG expression  
We have previously described a screening tool for the identification of monogenic 
type I interferonopathies based on qPCR assessment of six ISGs expressed by 
leukocytes (Rice et al., 2013; Rice et al., 2016). In this test, the median fold change 
of the ISGs when compared to the median of healthy controls is used to create an 
IFN score. Scores two standard deviations above the median of 29 controls are 
designated as positive (score of > 2.466). We compared Simoa IFNα measurements 
with the ISG score of samples from 31 SLE (Fig. 3 C), 24 JDM (Fig. 3 D) and 29 
monogenic interferonopathy (Fig. 3 E) (Table S8) patients, excluding patients who 
had negative results for both tests (10 SLE and 1 JDM patients). This analysis 
revealed a positive correlation between the two parameters in all three groups (SLE, 
Rs = 0.787, p < 0.0001 (n = 31); JDM, Rs = 0.665, p = 0.0004 (n = 24); 
interferonopathies, Rs = 0.635, p = 0.0002 (n = 29)). As type I interferonopathies are 
associated with a broad range of phenotypes at least partially determined by 
genotype, we grouped patients according to identified mutations (colour coded in Fig. 
3 E), but this did not obviously affect the correlation (data not shown). To note, two 
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outliers in the SLE cohort showed high ISG expression with no detectable IFNα and 
vice versa, although the explanation for such phenotypes is not clear. 
 
Association of disease phenotypes with serum IFNα in lupus patients 
To examine whether serum IFNα concentrations were relevant to disease status we 
focused on the SLE cohort. SLE is a complex and heterogeneous disease, and as 
such a number of different biomarkers are used to monitor disease severity and 
progression. For this analysis we divided the SLE patients into 3 groups based on 
serum IFNα concentrations; < 10 fg/ml (n = 25), 10 - 300 fg/ml (n = 14), > 300 fg/ml 
(n = 8), (Fig. 4) and in these subgroups examined (A) SLEDAI (systemic lupus 
erythematosus disease activity index), (B) ESR, (C) CH50 activity, (D) number of 
autoantibodies, and (E) profile of autoantibodies directed against ribonucleoproteins. 
An ANOVA with Dunn’s post testing revealed significantly higher α-RNP antibodies 
(p < 0.0001), ESR (p < 0.01), and SLEDAI (p < 0.01), and lower CH50 activity (p < 
0.001) in the patients that had highest serum IFNα. In contrast, anti-ds DNA 
antibodies and CRP activity showed no differences between the subgroups (Table 
S9).  
 
Identification of cellular sources of IFNα 
To explore cellular mechanisms driving disease pathogenesis, we next considered 
the source of IFNα detected in patients. We sampled blood from 3 STING, 4 AGS, 3 
JDM, 3 SLE patients and 4 healthy donors, and isolated CD4+ and CD8+ T cells, B 
cells, NK cells, CD14+ monocytes and pDCs. A representative flow cytometry panel 
with the gating strategy is shown in Fig. S2. The percentage of each cell population 
is presented in Table S10, the purity of sorted cell numbers are detailed in the 
materials and Table S11, and clinical characteristics of these patients are detailed in 
Table S12. Cell subsets were isolated, lysed and assessed with our IFNα Simoa 
assay. To calculate the level of protein present per cell, we divided the concentration 
of IFNα by the number of cells sorted and normalized for the volume in which the 
cells were lysed. This revealed a striking presence of IFNα in the monocytes and 
pDCs of STING patients, with a mean of 1.03 attogram/cell in pDCs and 1.53 
attogram/cell in monocytes (Fig. 5). Notably, no other cell types from the STING 
patients, nor any cell type analysed from the other patient groups tested, 
demonstrated levels of IFNα above those in healthy controls. This was despite the 
high levels of IFNα observed in plasma, suggesting a non-circulating cellular source 
of IFNα protein in these diseases. This discrepancy in the cellular source of IFNα 
between monogenic interferonopathy patients highlights a potential cell type specific 
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mechanism dependent on genes involved in nucleic acid metabolism or sensing.  
 
In conclusion, we report here that the ultrasensitive detection of IFNα protein in 
human material can provide novel insights into disease causing pathways. The 
transformational increase in sensitivity over conventional methods that we present 
here derives from the combination of the Simoa digital ELISA, and the extremely high 
affinity of the human monoclonal antibodies (mAbs) isolated from APS1/APECED 
mutation patients (Meyer et al., 2016). In this way, we were able to identify circulating 
pDCs and monocytes as a constitutive source of IFNα protein in STING mutation 
patients. Although pDCs are recognised as the major type I IFN producing leukocyte 
(Siegal et al., 1999), they were not apparently implicated in AGS, JDM or SLE 
patients in our study, possibly suggesting tissue sequestration of these cell types or 
an additional cellular source of IFNα in these conditions. However, the number of 
pDCs isolated was low, in particular from SLE patients, so that these results will 
require additional confirmatory experiments. The current lack of a test to measure 
type I IFN protein in routine medical practice represents a major unmet clinical need. 
The potential of direct measurement of IFN protein per se as a disease biomarker is 
obvious, and will be immediately relevant in SLE where anti-IFNα and anti-IFNAR 
therapies are currently being tested (Lauwerys et al., 2014). Indeed, our data 
identified lupus patients with low or high IFNα concentration, which differentiated 
patients based on a number of disease relevant phenotypes, and as such could be 
used for future patient stratification, as well as for on-treatment monitoring. Such 
changes might also be of clinical relevance in other situations, as evidenced by the 
risk of developing IFN-driven pathology in the context of TNFα blockade (Conrad et 
al., 2015). Furthermore, our ability to detect and quantify IFNα in different sample 
types from virally infected patients suggests possible clinical utility in the assessment 
of disease severity. For these reasons, we consider that digitalised ELISA technology 
can play a central role in future management of many different disease states. 
 
Methods  
 
Subjects and samples 
Historical serum, plasma and CSF samples were collected from patients 
demonstrating the presence of biallelic mutations in TREX1, RNASEH2A, 
RNASEH2B, RNASEH2C, SAMHD1 and ADAR1, as well as recognised dominant 
disease-causing mutations in TREX1, and from patients with dominant mutations in 
IFIH1 and TMEM173 (STING). Samples from patients with systemic lupus 
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erythematosus (SLE) and dermatomyositis (DM) demonstrated clinical criteria 
conforming to American College of Rheumatology and Bohan and Peter criteria 
respectively. Historical samples for IFN activity studies were collected across the 
period 1985 – 2015. All samples were collected with informed consent. The study 
was approved by the Leeds (East) Research Ethics Committee (reference number 
10/H1307/132), and by the Comité de Protection des Personnes (ID-RCB / 
EUDRACT: 2014-A01017-40). In Figure 2, only the first sample collected from each 
individual patient was plotted (Table S1-S5). For the correlation analysis in Fig. 3, 
serial samples from the same patient were used (Tables S7 and S8). SLE disease 
activity was assessed by an experienced rheumatology nurse specializing in SLE, 
who interviewed each patient and had access to all medical data and blood results 
using the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI). 
SLE Patients also had blood tests at the relevant clinic visits including that for SLE 
disease activity (C3, C4, and anti–double stranded DNA) and for routine 
inflammatory markers (CRP and erythrocyte sedimentation rate (ESR)), which were 
performed in a fully accredited, NHS laboratory (http://www.edinburghlabmed.co.uk). 
 
Simoa assay development 
The Simoa IFNα assay was developed using a Quanterix Homebrew Simoa assay 
according to the manufacturer’s instructions, and utilizing two autoantibodies specific 
for IFNα isolated and cloned from 2 APS1/APECED patients recently described 
(Meyer et al., 2016 and patent application WO2013/098419). The 8H1 antibody clone 
was used as a capture antibody after coating on paramagnetic beads (0.3mg/ml), 
and the 12H5 was biotinylated (biotin/Ab ratio = 30/1) and used as the detector. EC50 
binding of the mAbs was determined by ELISA as previously described (Meyer et al., 
2016), and observed to be 4.02 ng/ml and 4.4 ng/ml for 8H1 and 12H5 respectively, 
for IFNα5. The IC50 was determined using an ISRE-Luciferase reporter assay 
(described in Meyer et al., 2016), with results presented for both antibodies against 
all IFNα subtypes in Fig. S1 A. For the Simoa assay, recombinant IFNα17/αI (PBL 
Assay Science) was used as a standard curve after cross-reactivity testing (Fig. 1 B). 
The limit of detection (LOD) were calculated by the mean value of all blank runs + 
3SDs and was 0.23 fg/ml. Non-specificity was demonstrated against IFNβ, IFNλ1, 
IFNλ2, IFNω, and IFNγ (Peprotech & PBL Assay Science), and cross reactivity was 
tested against IFNα1, IFNα1 (Val114), IFNα2b, IFNα4a, IFNα4b, IFNα5, IFNα6, IFNα7, 
IFNα8, IFNα10, IFNα14, IFNα16, IFNα17, IFNα21 (all PBL Assay Science), IFNα2a 
(Peprotech) and IFNα2c (eBioscience). Additional specificity of the assay was 
demonstrated in a competition assay where SLE patient plasma samples (n = 5) 
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were 1/3 diluted with PBS and pre-incubated with the IFNα capture antibody (50 
μg/ml) for 30 minutes at room temperature prior to Simoa analysis. For Simoa 
measurements, biological samples were diluted from 1/3 to 1/30 depending on the 
amount of material available and to avoid saturation. Samples with signal below the 
LOD were normalized to 0.69 fg/ml (LOD*3, the minimal dilution factor) for 
presentation and analysis purposes. 
 
Interferon activity assay 
Type I IFN activity was measured by determining the cytopathic reduction i.e. 
protection of Madin-Darby bovine kidney cells against cell death following infection 
with vesicular stomatitis virus, afforded by patient CSF / serum. A reference of 
human IFNα, standardized against the National Institutes of Health reference Ga 
023-902-530, was included with each titration. IFNα activity in normal healthy serum 
is < 2 IU/ml.  
 
Assessment of interferon stimulated gene expression in blood cells 
Blood was collected into PAXgene tubes (PreAnalytix) and total RNA was extracted 
using a PAXgene (PreAnalytix) RNA isolation kit. RNA concentration was assessed 
using a spectrophotometer (FLUOstar Omega, Labtech). Quantitative reverse 
transcription polymerase chain reaction (qPCR) analysis was performed using the 
TaqMan Universal PCR Master Mix (Applied Biosystems), and cDNA derived from 
40ng total RNA. Using TaqMan probes for IFI27 (Hs01086370_m1), IFI44L 
(Hs00199115_m1), IFIT1 (Hs00356631_g1), ISG15 (Hs00192713_m1), RSAD2 
(Hs01057264_m1), and SIGLEC1 (Hs00988063_m1), the relative abundance of 
each target transcript was normalised to the expression level of HPRT1 
(Hs03929096_g1) and 18S (Hs999999001_s1), and assessed with the Applied 
Biosystems StepOne Software v2.1 and DataAssist Software v.3.01. For each of the 
six probes, individual (patient and control) data were expressed relative to a single 
calibrator (control C25). The median fold change of the six ISGs, when compared to 
the median of the combined 29 healthy controls, was used to create an interferon 
score for each patient. RQ is equal to 2-ΔCt i.e. the normalized fold change relative to 
a control. When a patient was assayed on more than one occasion, the data for 
repeat measurements were combined to calculate a mean value (using Applied 
Biosystems DataAssist software v.3.01).  
 
Cell sorting and lysis for Simoa analysis 
PBMCs were isolated from blood using lymphocyte separation medium. Just after 
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isolation, PBMCs were labeled with CD3 Krome Orange, CD8 pCp-Cy5, CD11c PE, 
CD19 PE-Cy7, CD56 FITC, CD14 APC-Alexa Fluor 750 and HLA-DR Pacific Blue. 
PBMC subsets were isolated using a BD FACS Aria II according to the gating 
strategy presented in Figure S1. Purity of the cell sorting was verified for 9 individual 
donors, and was high for all populations (mean +/- SD for CD4: 97% +/- 3.2, CD8: 
97.2% +/- 1.4, B cells: 97.5% +/- 2.3, NK: 97.9% +/- 1.6, monocytes: 97.7% +/- 2.6, 
pDCs: 96.9% +/- 2.3). After sorting, cells were pelleted and lysed in 50µl of RIPA 
buffer containing 1x of Halt Protease inhibitor Cocktail. Details of cell numbers and 
IFNα concentration are indicated in Table S11. Clinical characteristics of these 
patients are described in Table S12. Cell populations were not sorted from virally 
infected patients because of ethical restrictions on obtaining sufficient blood volumes. 
 
Statistical analysis 
GraphPad Prism was used for statistical analysis. ANOVA tests (Kruskal-Wallis) with 
Dunn’s post testing for multiple comparisons were utilized to test for differences 
between patient groups, with median and IQ ranges reported. Correlations between 
the different assays were calculated using Spearman test. 
 
Supplemental Information 
Supplemental Figures S1 shows affinity measurements of the antibodies used in the 
Simoa assay, S2 the gating strategy for cell sorting, and supplemental Tables S1-7 
list clinical characteristics of the patient cohorts. 
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Figure legends 
 
Figure 1. Specificity, sensitivity, and reproducibility of the Simoa IFNα assay. 
(A) Simoa IFNα assay reactivity with IFNα17, IFNβ, IFNλ1, IFNλ2, IFNω and IFNγ 
recombinant proteins. Lowest concentration is the blank. (B) Simoa IFNα assay 
cross-reactivity with IFNα1, IFNα1 (Val114), IFNα2a, IFNα2b, IFNα2c, IFNα4a, 
IFNα4b, IFNα5, IFNα6, IFNα7, IFNα8, IFNα10, IFNα14, IFNα16, IFNα17 and 
IFNα21. (C) Simoa IFNα competition assay; measurement of IFNα in 5 SLE patient 
plasma samples following pre-incubation with the human anti-IFNα capture antibody 
for 30 minutes prior to analysis. (D) Reproducibility testing for each concentration, 
acquired as duplicates across 3 independent runs. Dashed line represents the LOD, 
defined by mean blank AEB (Average Enzyme per Bead) + 3SD of all runs. (E) 22 
plasma samples (8 SLE, 8 DMJ, 3 AGS and 3 STING) were analysed with two 
independently prepared lots of beads, by different users and at different times, 
Spearman correlation is reported. (F) Correlation of IFNα protein measured by Simoa 
in paired plasma and serum samples from 10 AGS patients, Spearman correlation is 
reported. 
 
Figure 2. Quantification of plasma, serum, and CSF IFNα in patient cohorts. (A) 
Plasma from healthy controls (n = 20) and patients with RVCL (n = 30), SLE (n = 72), 
JDM (n = 43) and molecularly defined interferonopathies (n = 27) were assayed by 
Simoa for IFNα protein. Values were assessed by one-way ANOVA test (Kruskal-
Wallis), and Dunn’s multiple comparison testing between groups. (B) CSF samples 
from acute meningitis (n = 9), acute encephalitis (n = 9), acute meningo-encephalitis 
(n = 1), and RVCL (n = 12) were assayed by Simoa for IFNα protein. Values were 
assessed by Mann-Whitney T test., *** p < 0.001, **** p < 0.0001. 
 
Figure 3. Comparison of IFNα concentration with anti-viral activity and ISG 
expression. (A) Correlation of Simoa IFNα protein measurement with IFN activity 
measured by a cytopathic assay for interferonopathy (n = 10), JDM (n = 26), and 
JSLE (n = 2) patients. (B) Correlation of Simoa IFNα protein measurement with IFN 
activity measured by a cytopathic assay for CSF samples from acute viral meningitis 
(n = 9), acute viral encephalitis (n = 9), acute viral meningo-encephalitis (n = 1), AGS 
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(n = 1), and RVCL (n = 12). (C-D-E). Correlation of Simoa IFNα concentration with 
the ISG score in SLE (C, n = 21), JDM (D, n = 23), and molecularly defined 
interferonopathy patients (E, n = 29). Spearman correlations were calculated for each 
patient group, excluding samples where both the ISG score and the IFNα 
concentration were negative (SLE n = 10, JDM n = 1). 
 
Figure 4. Disease associations of serum IFNα in SLE patients. Higher serum 
IFNα levels associate with (A) Higher SLEDAI (systemic lupus erythematosus 
disease activity index) (p < 0.001), (B) ESR (p < 0.01), (C) lower CH50 activity (p < 
0.001) and (D) number of specific auto-antibodies against ribonucleoproteins (anti-
Ro, La, Sm, RNP) (p< 0.0001). IFNα <10 fg/ml: n = 25; IFNα = 10 - 300 fg/ml: n = 14; 
IFNα >300 fg/ml: n = 8, one-way ANOVA (Kruskal-Wallis) p values are reported. (E) 
Profile of autoantibodies directed against ribonucleoproteins in patients with low, 
intermediate and high IFN levels. Green = < 25U/ml, yellow = 25 - 50U/ml, orange = 
50 - 100 U/ml, red = over 100 U/ml. A positive result is > 25 U/ml. The total number 
of autoantibodies against ribonucleoproteins (anti-Ro, La, Sm, RNP) is significantly 
increased in patients with the highest levels of serum IFNα (2-way ANOVA, p < 
0.0001). * p < 0.05, **p < 0.01 ***p < 0.001 ****p < 0.0001.  
 
Figure 5. Identification of circulating IFNα producing cells in STING patients. 
IFNα protein levels presented as median attograms per cell in sorted CD4 and CD8 T 
cells, NK cells, B cells, monocytes and plasmacytoid dendritic cells (pDCs) from 
STING mutation (red, n = 3), JDM (blue, n = 3), AGS (green, n = 4) and SLE (purple 
n = 3) patients. The black line on each plot represents the median of 4 control 
healthy donors. 
 
Figure S1. IC50 values of mAbs used in Simoa assay for all IFNα subtype 
10,000 HEK 293 MSR cells were seeded in white half-area 96-well plates (Cat. No. 
3688, Corning) and reverse-transfected with 50 ng of premixed ISRE-Firefly 
luciferase reporter and Renilla luciferase constructs (Cat. No. CCS-008L, Qiagen, 
Hilden, Germany) using Fugene HD according to the manufacturer’s instructions 
(Promega, Madison, WI, USA). The Renilla luciferase-expressing construct served 
as an internal normalization control. Cells were incubated overnight in Opti-MEM® I 
Reduced Serum Medium supplemented with 0.1 mM non-essential amino acids, 1 
mM sodium pyruvate, 0.5% fetal bovine serum (Life Technologies, Carlsbad, CA, 
USA) at 37°C, 5% CO2 in a humidified atmosphere. Following overnight incubation, 
cells were stimulated for 24 hours with medium containing mixtures of recombinant 
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human IFNα with or without anti-IFNα mAbs or control IgG that had been pre-
incubated for one hour at 37°C. After 24 hours of stimulation, dual luciferase reporter 
assays were performed according to the manufacturer’s instructions (Promega). 
 
Figure S2. Flow cytometry gating strategy.  
Flow cytometry gating strategy for the isolation of CD8+ and CD4+ T cells, B cells, NK 
cells, monocytes and pDCs.  
 
Supplemental Tables 1 - 7. Clinical characteristics of patient cohorts and 
samples tested by IFNα Simoa assay, IFN activity assay and ISG score. 
 
Table S1. Retinal vasculopathy with cerebral leukodystrophy (RVCL). 
Table S2. Juvenile dermatomyositis (JDM).  
Table S3. Systemic lupus erythematosus (SLE).  
Table S4. Monogenic interferonopathy. 
Table S5. Central nervous system inflammation. 
Table S6. Controls. 
Table S7. Information on data used for Figure 3A. 
Table S8. Information on data used for Figure 3C, D and E. 
Table S9. Demographic and clinical associations of raised serum IFNα levels in SLE 
patients. 
Table S10. Circulating leukocyte frequencies in STING, AGS, JDM, SLE and 
controls. 
Table S11. Sorted cell numbers and IFN concentrations. 
Table S12: Clinical information of patients studied for cell subset IFNα content. 
 
 







